SuperworthVaxcyte EPS PCVX
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$7.64
- Latest quarter, Q2 FY26
- −$1.97
- Fiscal year 2025
- −$5.63
Vaxcyte's earnings per share was −$7.64 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.97.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$5.63 | n/a |
| FY2024 | −$3.79 | n/a |
| FY2023 | −$4.07 | n/a |
| FY2022 | −$3.40 | n/a |
| FY2021 | −$1.92 | n/a |
| FY2020 | −$9.24 | n/a |
| FY2019 | −$13.24 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.97 | n/a | −$7.64 | |
| Q1 FY26 | −$2.30 | n/a | −$6.89 | |
| Q4 FY25 | −$1.81 | n/a | −$5.63 | |
| Q3 FY25 | −$1.56 | n/a | −$4.83 | |
| Q2 FY25 | −$1.22 | n/a | −$4.10 | |
| Q1 FY25 | −$1.04 | n/a | −$3.98 | |
| Q4 FY24 | −$1.01 | n/a | −$3.79 | |
| Q3 FY24 | −$0.83 | n/a | −$4.54 | |
| Q2 FY24 | −$1.10 | n/a | −$4.62 | |
| Q1 FY24 | −$0.85 | n/a | −$4.22 | |
| Q4 FY23 | −$1.76 | n/a | −$4.07 | |
| Q3 FY23 | −$0.91 | n/a | −$3.30 |
Against its peers
Companies in Biotechnology nearest Vaxcyte's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PCVXVaxcyte | −$7.64 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $4.64 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vaxcyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.